ENGLAND'S hopes of T20 World Cup and Ashes glory suffered a major setback on Thursday (5) when it was announced that fast bowler Jofra Archer would be sidelined for the rest of this year with an elbow injury.
The England and Wales Cricket Board said in a statement that scans last week on the currently sidelined 26-year-old's right elbow had revealed a recurrence of a stress fracture in his bowling arm.
"In response to these findings, he has been ruled out for the rest of the year and will miss the current Test series against India, the ICC Men's T20 World Cup 2021 and the Ashes series in Australia," the ECB added.
Archer, already absent from the ongoing first Test against India at Trent Bridge, was a central figure in 2019's World Cup triumph on home soil.
The paceman was considered vital to England's hopes of winning the T20 World Cup, in the UAE and Oman in October and November, and regaining the Ashes when a five-Test series begins in Australia in December.
Archer has taken 42 wickets at 31.04 in 13 Tests and 14 in 12 T20s at 26.50.
While those figures are not especially notable, Archer's two-year international career has already seen him produce several match-turning spells, with the Barbados-born quick entrusted with the Super Over in England's dramatic 2019 50-over World Cup final win over New Zealand at Lord's.
News of Archer's long absence was announced just days after England revealed that fellow World Cup-winner and star allrounder Ben Stokes was taking an indefinite break from all cricket to "prioritise his mental health".
England great James Anderson, speaking after stumps on Thursday's second day in the first of a five-Test series against India, said: "It's a huge disappointment for Jofra and the team.
"He's been a really influential part of the team for the last couple of years since he started playing for England, a huge miss with what's coming up in the rest of the year."
Anderson, sympathising with his fellow paceman, added: "I think also this injury has been bugging him for quite a while, hopefully now this can be the end of it - get it settled, get it healed, rehab it and come back stronger.
"He's been great for this team and we want him back, fully fit and firing."
'Game changer'
Earlier, former England captain Alastair Cook said he feared the injury was a "game changer" for Archer's career amid concerns the bowler may never again reproduce the searing speed that troubled Australia's batsmen during the drawn 2019 Ashes series.
"Tim Bresnan was never the same bowler after his elbow injury - they're so hard to get right," Cook told BBC Radio's Test Match Special.
"He lost that yard of pace and Jofra's point of difference is that he can bowl genuinely quick. It's a game changer," added Cook, who said he hoped advances in medicine would aid Archer's recovery.
Archer was first diagnosed with a stress fracture in his bowling arm after breaking down on the South Africa tour of 2019/20.
He has since been treated with cortisone injections in the joint, most recently during another injury-hit tour of India earlier this year.
Archer underwent surgery in May to remove a bone fragment, having had an operation in March to remove a piece of glass from his finger following a bizarre injury involving a dropped fish bowl.
Concerns about his fitness intensified after two appearances for Sussex saw him bowl just nine overs in total.
Of England's out-and-out quicks, only Mark Wood - whose career has been blighted by several ankle injuries - is currently fit.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.